


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11812163/publications.pdf Version: 2024-02-01



Bo Fu

#	Article	IF	CITATIONS
1	Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. New England Journal of Medicine, 2018, 378, 354-369.	27.0	361
2	Mild cognitive impairment. Neurology, 2013, 80, 2112-2120.	1.1	120
3	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology, 2018, 67, 505-513.	7.3	94
4	Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	38
5	Vascular Risk Factors and Cognitive Decline in a Population Sample. Alzheimer Disease and Associated Disorders, 2014, 28, 9-15.	1.3	35
6	Old Worries and New Anxieties: Behavioral Symptoms and Mild Cognitive Impairment in a Population Study. American Journal of Geriatric Psychiatry, 2014, 22, 274-284.	1.2	32
7	High antiviral activity of <scp>NS</scp> 5A inhibitor <scp>ABT</scp> â€530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver International, 2016, 36, 1125-1132.	3.9	14
8	Hepatitis C in Liver Allograft Recipients: Utility of One-Year Post-Transplantation Biopsy as an Indicator of Antiviral Therapy. Gastroenterology Research, 2015, 8, 281-290.	1.3	0